Sellas Life Sciences Stock Performance
| SLS Stock | USD 1.20 0.01 0.83% |
On a scale of 0 to 100, Sellas Life holds a performance score of 7. The entity has a beta of 1.19, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Sellas Life will likely underperform. Please check Sellas Life's value at risk, as well as the relationship between the kurtosis and market facilitation index , to make a quick decision on whether Sellas Life's existing price patterns will revert.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Sellas Life Sciences are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak essential indicators, Sellas Life unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:50 | Dividend Date 2019-11-08 | Last Split Date 2019-11-08 |
1 | Acquisition by Cicic Dragan of 169500 shares of Sellas Life at 0.9525 subject to Rule 16b-3 | 01/10/2025 |
2 | Acquisition by Varian John of 7125 shares of Sellas Life at 5.34 subject to Rule 16b-3 | 01/17/2025 |
3 | SELLAS Life Sciences Group Sees Unusually High Options Volume | 01/23/2025 |
4 | SELLAS Life Sciences Group Target of Unusually Large Options Trading - MarketBeat | 01/24/2025 |
5 | SELLAS Life Sciences Group Announces 25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | 01/28/2025 |
6 | SEC Form 424B5 filed by SELLAS Life Sciences Group Inc. - Quantisnow | 01/29/2025 |
7 | Is the ASX Materials Sector Setting New Market Standards | 02/05/2025 |
8 | SELLAS Life Sciences Groups 25 Million Common Stock Offering - Global Legal Chronicle | 02/12/2025 |
9 | SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL | 02/20/2025 |
10 | Acquisition by Varian John of 10000 shares of Sellas Life at 0.5195 subject to Rule 16b-3 | 03/03/2025 |
11 | EnterOne adquiere SLS LATAM Argentina y Chile, ampliando su liderazgo en Amrica Latina | 03/06/2025 |
12 | Acquisition by Barbara Wood of 20000 shares of Sellas Life subject to Rule 16b-3 | 03/10/2025 |
| Begin Period Cash Flow | 2.6 M | |
| Free Cash Flow | -35.4 M |
Sellas |
Sellas Life Relative Risk vs. Return Landscape
If you would invest 91.00 in Sellas Life Sciences on December 23, 2024 and sell it today you would earn a total of 29.00 from holding Sellas Life Sciences or generate 31.87% return on investment over 90 days. Sellas Life Sciences is generating 0.7166% of daily returns assuming volatility of 7.6523% on return distribution over 90 days investment horizon. In other words, 68% of stocks are less volatile than Sellas, and above 86% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Sellas Life Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Sellas Life's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Sellas Life Sciences, and traders can use it to determine the average amount a Sellas Life's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0937
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | SLS | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 7.65 actual daily | 68 68% of assets are less volatile |
Expected Return
| 0.72 actual daily | 14 86% of assets have higher returns |
Risk-Adjusted Return
| 0.09 actual daily | 7 93% of assets perform better |
Based on monthly moving average Sellas Life is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Sellas Life by adding it to a well-diversified portfolio.
Sellas Life Fundamentals Growth
Sellas Stock prices reflect investors' perceptions of the future prospects and financial health of Sellas Life, and Sellas Life fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Sellas Stock performance.
| Return On Equity | -5.35 | ||||
| Return On Asset | -1.14 | ||||
| Current Valuation | 81.41 M | ||||
| Shares Outstanding | 78.58 M | ||||
| Price To Book | 9.96 X | ||||
| Price To Sales | 26.90 X | ||||
| Gross Profit | 900 K | ||||
| EBITDA | (31.51 M) | ||||
| Net Income | (30.88 M) | ||||
| Cash And Equivalents | 26.99 M | ||||
| Cash Per Share | 1.31 X | ||||
| Total Debt | 1 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 2.36 X | ||||
| Book Value Per Share | 0.25 X | ||||
| Cash Flow From Operations | (35.4 M) | ||||
| Earnings Per Share | (0.50) X | ||||
| Market Capitalization | 94.3 M | ||||
| Total Asset | 19.43 M | ||||
| Retained Earnings | (248.12 M) | ||||
| Working Capital | 6.82 M | ||||
About Sellas Life Performance
Assessing Sellas Life's fundamental ratios provides investors with valuable insights into Sellas Life's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Sellas Life is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -23.1 K | -21.9 K | |
| Return On Tangible Assets | (1.76) | (1.85) | |
| Return On Capital Employed | (3.18) | (3.33) | |
| Return On Assets | (1.59) | (1.67) | |
| Return On Equity | (3.26) | (3.43) |
Things to note about Sellas Life Sciences performance evaluation
Checking the ongoing alerts about Sellas Life for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Sellas Life Sciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Sellas Life Sciences is way too risky over 90 days horizon | |
| Sellas Life Sciences may become a speculative penny stock | |
| Sellas Life Sciences appears to be risky and price may revert if volatility continues | |
| Reported Net Loss for the year was (30.88 M) with profit before taxes, overhead, and interest of 900 K. | |
| Sellas Life Sciences has about 26.99 M in cash with (35.4 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.31, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Sellas Life Sciences has a frail financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Acquisition by Barbara Wood of 20000 shares of Sellas Life subject to Rule 16b-3 |
- Analyzing Sellas Life's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Sellas Life's stock is overvalued or undervalued compared to its peers.
- Examining Sellas Life's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Sellas Life's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Sellas Life's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Sellas Life's stock. These opinions can provide insight into Sellas Life's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Sellas Stock Analysis
When running Sellas Life's price analysis, check to measure Sellas Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sellas Life is operating at the current time. Most of Sellas Life's value examination focuses on studying past and present price action to predict the probability of Sellas Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sellas Life's price. Additionally, you may evaluate how the addition of Sellas Life to your portfolios can decrease your overall portfolio volatility.